FY2025 · ended Dec 31, 2025 · Revenue $9.10M, +0.2% YoY · Filed Mar 30, 2026
International Stem Cell Corporation (ISCO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $9.1 million and a net loss of $418,000. Free cash flow was -$35,000. As of Jun 30, 2026 it held $1.1 million in cash and investments and $199,000 in total debt.
Revenue (TTM)
$9.51M
+3.4% vs year-ago TTM
Net income (TTM)
$-582,000
-141.5% vs year-ago TTM
Operating cash flow (TTM)
$369,000
+235.5% vs year-ago TTM
Free cash flow (TTM)
$333,000
+851.4% vs year-ago TTM
EPS (TTM)
$-0.07
-141.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
8.00M
+0.0% vs prior year
Net cash
$890,000
as of Jun 30, 2026
Operating margin
-4.7%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ISCO (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1355790
- Former names
- BTHC III INC. (until Jan 19, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $9.1M | $9.1M | $7.8M | $8.2M | $7.2M |
| Operating income | -$267,000 | -$68,000 | -$663,000 | -$183,000 | -$1.9M |
| Net income | -$418,000 | -$209,000 | -$131,000 | -$331,000 | -$899,000 |
| Diluted EPS | -$0.05 | -$0.03 | -$0.02 | -$0.04 | — |
| Operating cash flow | $8,000 | $13,000 | $929,000 | $332,000 | -$1.3M |
| Free cash flow | -$35,000 | -$153,000 | $849,000 | $331,000 | -$1.3M |
| Total assets | $4.8M | $5.2M | $5.4M | $5.1M | $4.9M |
| Total liabilities | $4.6M | $4.8M | $5.3M | $5.4M | $5.2M |
| Stockholders' equity | -$4.1M | -$3.9M | -$4.2M | -$4.5M | -$4.6M |
| Cash and investments | $993,000 | $1.2M | $1.6M | $742,000 | $171,000 |
| Total debt | $393,000 | $445,000 | $721,000 | $950,000 | $1.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Acquisition or sale of assets
|
Sep 8, 2026 | Sep 1, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 16, 2026 | Jul 10, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 11, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| ARS | Annual report to shareholders | Apr 29, 2026 | Dec 31, 2025 |
All 825 International Stem Cell Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.